In particular, PGD2 has been recognized as a tumor suppressor via the PGD2 receptor in colitis-associated colon cancer (33), and PGI2 is capable of recruiting CD4+ T cells in MHC class II–expressing murine lung cancer cells (34). Here, CD4 is linked to malignant colon neoplasm.